Scholarlink

<p>Adherence to positive airway pressure (PAP) therapy is a challenge in patients with allergic rhinitis. We present a case of a 62-year-old male with OSA who had been struggling with PAP therapy for 10 years. Intranasal fluticasone alone did not result in tolerance of PAP therapy. However, the combination of once-daily intranasal oxymetazoline with fluticasone led to significant improvement in tolerance and adherence to PAP therapy. Although twice-daily oxymetazoline alone has been associated with developing rhinitis medicamentosa, this side effect was not experienced by our patient. Some studies have shown that using intranasal oxymetazoline along with an intranasal steroid once daily for 4 weeks demonstrated improved effectiveness in relieving nasal symptoms with no development of rebound congestion or rhinitis medicamentosa. This strategy may be helpful in improving continuous PAP tolerance for patients with concurrent obstructive sleep apnea and rhinitis, a potential area to explore in the future to improve PAP adherence.</p> Citation: <p>Anokwute A, Manchanda S, Wallach PM. Improvement of CPAP tolerance and adherence in a patient with obstructive sleep apnea with the use of nasal steroids and nasal oxymetazoline. <i>J Clin Sleep Med.</i> 2025;21(4):733–734.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improvement of CPAP tolerance and adherence in a patient with obstructive sleep apnea with the use of nasal steroids and nasal oxymetazoline

  • 期刊论文

  • 发表日期：

    2025年4月1日

查看全文
  • Akudo Anokwute,
  • Shalini Manchanda,
  • Paul M. Wallach

摘要

Adherence to positive airway pressure (PAP) therapy is a challenge in patients with allergic rhinitis. We present a case of a 62-year-old male with OSA who had been struggling with PAP therapy for 10 years. Intranasal fluticasone alone did not result in tolerance of PAP therapy. However, the combination of once-daily intranasal oxymetazoline with fluticasone led to significant improvement in tolerance and adherence to PAP therapy. Although twice-daily oxymetazoline alone has been associated with developing rhinitis medicamentosa, this side effect was not experienced by our patient. Some studies have shown that using intranasal oxymetazoline along with an intranasal steroid once daily for 4 weeks demonstrated improved effectiveness in relieving nasal symptoms with no development of rebound congestion or rhinitis medicamentosa. This strategy may be helpful in improving continuous PAP tolerance for patients with concurrent obstructive sleep apnea and rhinitis, a potential area to explore in the future to improve PAP adherence.

Citation:

Anokwute A, Manchanda S, Wallach PM. Improvement of CPAP tolerance and adherence in a patient with obstructive sleep apnea with the use of nasal steroids and nasal oxymetazoline. J Clin Sleep Med. 2025;21(4):733–734.